Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 8351 - 8375 of 8875 in total
Barnidipine is a long-acting novel calcium antagonist that belongs to the dihydropyridine (DHP) group of calcium channel blockers. Used in the treatment of hypertension, barnidipine displays high affinity for the calcium channels of the smooth muscle cells in the vascular wall and selectivity against cardiovascular L-type calcium channels . Barnidipine...
Experimental
Azelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate, unlike some other calcium channel blockers . It is currently being...
Investigational
Fimepinostat (CUDC-907) has been used in trials studying the treatment of lymphoma, solid tumors, breast cancer, multiple myeloma, and NUT midline carcinoma, among others.
Investigational
VNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
Investigational
A metabolite from Penicillium brefeldianum that exhibits a wide range of antibiotic activity.
Experimental
Experimental
Trimazosin is a sympatholytic alpha blocker.
Experimental
beta-Apopicropodophyllin is a component of the freshwater plant Micranthemum umbrosum.
Experimental
CP-866,087 has been used in trials studying the treatment of Obesity, Alcoholism, and Sexual Dysfunction, Physiological.
Investigational
Vinpocetine has been investigated for the treatment of Epilepsy.
Investigational
CXL-1020 is under investigation in clinical trial NCT01092325 (Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure).
Investigational
Displaying drugs 8351 - 8375 of 8875 in total